Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HGEN Watching close to see if Friday move off bottom can continue Monday..could be a strong play if so..
https://stockcharts.com/c-sc/sc?s=HGEN&p=D&b=5&g=0&i=0&r=1664639331984
"Management did mislead investors and now they are getting sued for it."
The Class Action is totally without merit. I've already presented information that supports my position.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170000838
Be sure to read a link in that post to another post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169869278
anyone can sue anyone ..... some make it part of their business plan.... just look at 45.
Management sucks and destroyed shareholders with there inability to do anything correctly
Dale SOLD shortly before the EUA DENIAL.
What is the Price Change Parity with BLUE now?
#LOLOL
Management did mislead investors and now they are getting sued for it. Who takes in on the chin - the investors of course.
You’re so full of it. I want this company to go up as much as anyone, but you keep pushing BS and nothing you have said has come true. Why don’t you tell us all how “It’s a pleasure to support management” again, as all of management leaves and the company nears bankruptcy. Just stop pushing the fluff
Same as before, nothing really new there
You want to give management crap for doing such a "terrible job," right? What THEY did was to achieve a successful Phase III trial outcome. What THEY did was to prove a causal relationship between elevated levels of GM-CSF and CRP, to disease severity. What THEY did was to show unparalleled treatment outcomes, especially for the Black and African/American population.
My question is, did they discover a cure for Covid, when administered early in the disease progression? How many lenz patients, treated while in ordinal scale 4 or 5, suffered breakthrough infections?
I really want to see the ACTIV-5 Final Report. NIAID may have chosen to include patients in their trial that were in ordinal scale 7, but by their own trial criteria, the primary outcome is not to be measured against patients who had progressed to that stage at baseline.
"Primary Outcome Measures
Occurrence of mechanical ventilation or death at any point through Day 29 in subjects with ordinal scores of 5 or 6 at baseline"
https://clinicaltrials.gov/ct2/show/NCT04583969?term=lenzilumab&draw=2&rank=4
Two massive failures and near bankruptcy. No one will trust management ever again. All credibility is gone, stop pumping nonsense
This company is prepared for trouble. They have been, since January of 2016.
You know darn well that he bailed and this company is in trouble
There's no way out for NIAID, should their Final Report and Conclusion from ACTIV-5 be unfavorable. I don't know why the hell they might be thinking otherwise. An unfavorable Conclusion will likely subject them to Discovery, and I am sure that sufficient probable cause exists to obtain their data, if necessary.
Morris' 30 day notice was a decent gesture.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465922011700/r9282248k.htm
"So many questions that need answering. . . ."
I agree. I can easily understand why Dale went into the research arena after getting his MD, and why he is our CSO instead of our CMO. Posts in this thread talk about Nathaniel Landau and his colleagues finding a cure for HIV. "We were sleeping in the lab, just to keep the work going day and night because there were many labs all racing against each other..." Sounds just like what Watson and Crick went through in identifying the structure of DNA.
And I think that's where we are with lenz, just beginning to realize it's potential. And it's a door that only we can unlock, with our intellectual property rights, which cost us $10M more to safeguard those rights, than the current value of our market cap. I hope management can find a way to enable shareholders to be rewarded by the potential of lenz, as that potential becomes realized.
I had not heard of NAC before, although I was already taking glutathione for another reason, along with broccoli seed derivative. Interesting post which has me now looking into this more thoroughly.
Regarding "things such as my smoking, and my weight (now over 200 pounds) on my 5'10" frame, I remain covid-free, despite being a model covid victim. And I am now being treated for peripheral artery disease (PAD), which is another reason Iope lenz will be there for me. So, am I a covid "superdodger?" Or is it likely I'm covid-free because I am pretty much a hermit?"
That entire post was of interest to me because you could be describing my husband and I (except for the mono part, although husband has had more issues over the years than most can shake a stick at, and as I've mentioned previously, is immuno-compromised, and has ankylosing spondylitis, which on its own causes a host of health issues in addition to the basic arthritic effects). We are both ex-smokers (me heavily, and I still occasionally vape), and while his weight is below his normal, I've been battling the weight creep of many over 65, and while not obese, weigh more than I should. And we are hermits as well. Even before covid hit. And Covid was in our house before either of us got jabbed, courtesy of one of my sons, and we had no way to fully isolate him. Why did neither of us get it? (At least, we never tested positive, even though several months prior we both felt "bleah" for a few days about a week after we had traveled back from Maine, and wondered then if we had it.) We are both actually waiting now to see if we were exposed last week in NYC, where husband had to have a specialized angioplasty procedure done, and we were around TONS of people all week (and I got behind reading IHub posts. . . .)
So many questions that need answering. . . .
What is the Price Change Parity with BLUE now?
#LOLOL
I now have 22 times the number of shares I averaged over the last really 3 years... I am hoping shorty can keep this thing low till Friday morning : )
You got called out on Twitter for manipulation and posting from multiple accounts
A real linchpin at this point is the Transfer Agent. Ours seems to fully understand the rule of law, from what little I have seen.
But that has not always been my experience with other transfer agents, one of whom was issued a cease and desist order, and was forced to disgorge his ill-gotten gain, plus interest and penalties.
https://www.sec.gov/litigation/admin/2017/33-10303.pdf
A toxic lender in that case was also involved in a separate company. That company's TA was charged with the unauthorized selling of one billion shares of the company, and then having the proceeds of that sell wired into his personal bank account.
Management has said they learned a lot about how governmental agencies work, and about our competitors' behavior. But you can't always trust gatekeepers, either.
This is the last week of the 3rd Quarter, and I think snakes in the grass may be a moot concern by now. But that may not be. I like what I am seeing, and that includes what appears to be the 66% short volume Friday. "The short sale volume percent (not short interest) for stock ticker HGEN is 66% on Sep 23, 2022."
http://shortvolumes.com/?t=HGEN
$HGEN Hello beautiful! Looks like a near perfect bottom play here with strong volume Friday..
https://stockcharts.com/c-sc/sc?s=HGEN&p=D&b=5&g=0&i=0&r=1664105738434
It’s a con. No reason in the world to believe it. This company is on life support right now financially and no one would consider buying it.
It’s a con. No reason in the world to believe it. This company is on life support right financially now and no one would consider buying it.
Im in a similar postion. Averaged down with .15 and will continue to wait for the ride or die.
What else is there to do?
Good to hear from you DTG. Hope all is well!
Someone posted on Stocktwits that they got a message about a rumor that the company was being bought out. Anyone receive that same message? Please post if so
We got some price movement in the up direction but I cannot find any news. Seeing if any of you all heard anything.
Sorry this didn't work out here my friend. I and my wife purchased 2,500 shares at .60 cents thinking it was going to be great. Today at .15 cents that did not work out very well. Glad my bet was only $1500. At this point it doesn't pay to sell down here so we will just wait this one out.
Lawsuit, Reverse Split, or Delisting? Whats next?
This dream turned to nightmare fast. Very disappointed in how management has handled this situation.
Those that say its years away from Revenue are unfortunately correct. There will be nothing to support the price here. Hence the continuous free fall of the price.
This was a big learning experience, my only take away.
5 amputations due to Covid huh? You spend a lot of time trolling this board everyday, kinda sad
Covid-associated brain injury and blood clotting. The very indications my wife developed, which led to impaired hearing, speech, sight, and motor control, as well as to five amputations resulting in the loss of both of her legs. The reasons I tried talking the doctors into giving her lenz. So now I am beginning to hope that lenz will be there for me, and the tens of millions of patients who already have these post-covid neurological and inflammation indications.
"COVID raises risk of long-term brain injury, large U.S. study finds"
https://www.yahoo.com/news/covid-raises-risk-long-term-150329709.html
What is the Price Change Parity with BLUE now?
#LOLOL
Well, that post is some babbling nonsense right there.
And so, unsurprising.
Something about a pergola and the Alamo facade again perhaps.
Mebbe send a letter to Steve Mnunchin.
LOL@ this pennyscam turd still being traded.
maybe he did cash i dont know.
lenzilu gelTabs will soon be for sale.
all we need is Steven Gundry…..
Hahaha think he was feeling really good after GME, but if this went the other way we’d be singing a different tune. It was looking pretty good two years ago when he first started touting it too. I was up then and should’ve sold in hindsight. Is what it is I guess
Hahaha think he was feeling really good after GME, but if this went the other way we’d be singing a different tune. It was looking pretty good two years ago when he first started touting it too. I was up then and should’ve sold in hindsight. Is what it is I guess
and the lord knows its time to bypass fda here.. even the greatest biggest baddest skeptics know it is very very very very very very safe to take. take a look at the top pin…
well he bragged about how many shares he had here and how much money he made off short sellers on other meme stocks. he went to lengths including publishing a story about his score( like 10 mm bucks)
im not blaming him though…
and im pretty sure he figured out it was not a great idea too.
im ready to buy a bottle of lenziluTabs for my anti aging daily regimine.
the world needs a good anti aging supplement
“Trap shut”? In what regard? Or do you mean at all, so you never heard of this company? We’re all responsible for our own decisions
institutional investors need to finish raping and pillaging first ….
sometimes i think MWM should have kept his trap shut, but i digress
You’re talking about executing a stock play by buying shares and then removing all loanable shares from the market. Something about cede shares being converted back into certificate form. I remember and would like to see something similar happen after the first Shkreli squeeze, but I’m not so sure that it will come to fruition or that the company is in the process of executing such a move. Insiders are also more than capable of doing this with insider buys and enriching themselves simultaneously. We haven’t seen that type of activity reflected in the market.
HGEN stock - Where money comes to die.....
i think its safe to say no one has any idea what you are talking about.
at least you know …..
for what it is worth pretty much nothing of what you have predicted has come about
Yeah, that wouldn't be cool. But the subject of how I think the share structure is designed is actually one that I have been discussing ever since I saw it laid out in a filing some years ago. This is only your 5th post on this board, so you may not be familiar with the history of these discussions. I will only say the purpose of the design may be in the realization phase now. If I see a contra-indication, I'll say so. But on the other hand, if I see additional confirmation, I won't say anything.
I wouldn't be saying now, either, if I hadn't earlier raised a possible concern. And I am only saying that I no longer have that possible concern.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
42494
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay TheGreatSwami |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |